You are here

Ancrod Development Continues to Phase 3 Trial

RICHMOND, Calif., March 14, 2005 /PRNewswire-FirstCall via COMTEX/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) today reported on an End of Phase II meeting with the Food and Drug Administration (FDA) regarding Viprinex(TM) (Ancrod), a product in clinical development for the treatment of acute ischemic stroke. As a result of the meeting, the company continues to move forward with its plan to commence a Phase III program this summer.

Paul E. Freiman, President and Chief Executive Officer, stated, "I am highly encouraged by the meeting though more work needs to be done over the next few weeks between the FDA and NTI regarding the design and finalization of the clinical program. We are moving in a careful stepwise fashion to accomplish the goal of entering the clinic this summer."

Viprinex has been studied in more than 2,000 patients in various clinical studies in the U.S. and Europe. The prior development work on Viprinex was conducted by Knoll AG, prior to its acquisition by Abbott in 2001. If successful, we believe that Viprinex may have the potential to double the available treatment window following the onset of stroke symptoms. Currently, the only available therapy for stroke must be administered within the initial three hours, significantly limiting the number of patients that may be treated.

Source: Neurobiological Technologies, Inc.

Recent Headlines

Triggers the Body’s Own Natural Blood Flow Regulation
Inrebic Reduces Symptoms by 50% in Some Patients
Novel Catheter-based Technology for Treating Acute Ischemic Stroke
Decision supported by data from more than 4,000 patients
Zip Device Faster to Apply, Minimizes Scarring
Statistically Significant Improvement in Excessive Daytime Sleepiness
Researcher Made Himself Guinea Pig to Test the Drug
Treatment Shorter, Less Complicated Than Typical Regimen